Contact this trialFirst, we need to learn more about you.
Proteasome Inhibitor
Quadruple Therapy for Multiple Myeloma
Recruiting1 awardPhase 2
Kansas City, Kansas
This trial is testing a new cancer drug. It's open-label, which means participants know what drug they're taking, and it's single-arm, which means everyone gets the same treatment. The safety lead-in phase is to make sure the drug is safe before giving it to everyone in the trial.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.